No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:

First-line immune checkpoint inhibitors plus targeted therapy versus sorafenib or lenvatinib monotherapy for unresectable or advanced hepatocellular carcinoma: a meta-analysis of phase 3 trials.

Lin Yuxuan, Liao Yonghe, Luo Bo et al. · Front Immunol · 2025

PMID: 41169385Meta-AnalysisFull text (PMC)

Effectiveness of sorafenib in combination with physical thermal ablation for hepatocellular carcinoma: A meta-analysis.

Wen Xiang, Qi Fuliang, Qian Hailong et al. · Adv Clin Exp Med · 2025

PMID: 40856086Meta-Analysis

Efficacy and safety of sorafenib combined with transarterial chemoembolization in the treatment of hepatocellular carcinoma: a meta-analysis of randomized controlled trials.

Yu Lixiu, Xiong Yi, Liao Jing et al. · Front Oncol · 2025

PMID: 41293272Meta-AnalysisFull text (PMC)

Optimal candidates and surrogate endpoints for HAIC versus Sorafenib in hepatocellular carcinoma: an updated systematic review and meta-analysis.

Si Tengfei, Shao Qing, Jassem Wayel et al. · Int J Surg · 2025

PMID: 39093862Meta-AnalysisFull text (PMC)

Efficacy of Lenvatinib Versus Sorafenib in the Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Remitha Ni Putu Sri Indrani, Dewi Ni Putu Rista Pradnya, Yogananda I Komang Chandra et al. · Asian Pac J Cancer Prev · 2025

PMID: 40542755Meta-AnalysisFull text (PMC)

Comparison of efficacy and safety of adjuvant therapies versus sorafenib in hepatocellular carcinoma: a systematic review and network meta-analysis.

Quan Wenjun, Fazlin Zulkifli Hanifah, Saari Norhafizah et al. · Front Pharmacol · 2025

PMID: 40098625Meta-AnalysisFull text (PMC)

Bibliometric study on the utilization of sorafenib in hepatocellular carcinoma.

Meng Wenjun, Luo Yihang, Zhao Lu et al. · Front Oncol · 2024

PMID: 39759148Meta-AnalysisFull text (PMC)

Prognosis of transarterial chemoembolization-sorafenib compared to transarterial chemoembolization-alone in hepatocellular carcinoma stage C: a systematic review.

Mulyadi Rahmad, Hasan Irsan, Sidipratomo Prijo et al. · J Egypt Natl Canc Inst · 2024

PMID: 38797810Meta-Analysis

The long-term efficacy and safety of apatinib are inferior to sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis.

Li Dailong, Zhang Chunzhen, Yang Kui et al. · Medicine (Baltimore) · 2024

PMID: 38241568Meta-AnalysisFull text (PMC)

Efficacy and safety comparison between Lenvatinib and Sorafenib in hepatocellular carcinoma treatment: a systematic review and meta-analysis of real-world study.

Hua Xuefeng, Yin Ziwei, Liang Jin et al. · Eur J Gastroenterol Hepatol · 2024

PMID: 37942731Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Sorafenib (substance)
SNOMED CT: 422042001
UMLS CUI: C1516119
RxNorm CUI: 495881
Labeler: Golden State Medical Supply, Inc.

Clinical Data

This intervention maps to 5 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.